OSLO, Norway, June 17 /PRNewswire-FirstCall/ --
- New Investigational Drug Also Shown to Improve Remission Rates and Reduce Short-Term Mortality Compared to Previous Treatments
Clavis Pharma ASA (OSE: CLAVIS) today announces positive final results from a Phase II trial of its novel investigational cancer drug, elacytarabine (CP-4055), in patients with late-stage acute myeloid leukaemia (AML). In the trial, elacytarabine showed statistically significant superior efficacy compared to published clinical data for late-stage AML. Based on these encouraging results an elacytarabine registration study is being planned.
Key results compared to published clinical data: - Median survival three times longer (5.5 months vs. 1.5 months) - Remission rate significantly increased (15% vs 2.5%, p<0.0001) - Well tolerated - short-term mortality substantially lower (13 per cent vs. 25 per cent)
Elacytarabine is a novel cytotoxic agent being developed by Clavis Pharma for the treatment of hematologic cancers and solid tumors, especially those resistant to existing agents. One particularly difficult-to-treat patient group is late-stage acute myeloid leukaemia (AML) patients who have failed two previous therapeutic regimens. There is currently no standard therapy available for these patients and life expectancy is very short. It is in this patient group that Clavis Pharma has evaluated the safety and efficacy of elacytarabine.
Extended survival, improved remissions
In the Phase II study, 61 patients with late stage AML who failed to
respond or relapsed after two separate rounds of treatments received
third-line therapy (also called second salvage) with intravenous
elacytarabine. The response to treatment was compared with a detailed
historical outcome analysis of 594 similar second salvage AML patients, who
were treated at the MD Anderson C
|SOURCE Clavis Pharma ASA|
Copyright©2009 PR Newswire.
All rights reserved